Lbp Am Sa Has $6.38 Million Position in Axon Enterprise, Inc (NASDAQ:AXON)

LBP AM SA lowered its position in Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 3.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 12,128 shares of the biotechnology company's stock after selling 465 shares during the period. LBP AM SA's holdings in Axon Enterprise were worth $6,379,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in AXON. Capital World Investors lifted its position in shares of Axon Enterprise by 86.4% during the 4th quarter. Capital World Investors now owns 1,815,765 shares of the biotechnology company's stock valued at $1,079,145,000 after acquiring an additional 841,772 shares during the period. Alliancebernstein L.P. lifted its position in shares of Axon Enterprise by 273.8% during the 4th quarter. Alliancebernstein L.P. now owns 1,109,045 shares of the biotechnology company's stock valued at $659,128,000 after acquiring an additional 812,337 shares during the period. Norges Bank acquired a new stake in shares of Axon Enterprise during the 4th quarter valued at approximately $482,081,000. GQG Partners LLC acquired a new stake in shares of Axon Enterprise during the 4th quarter valued at approximately $478,349,000. Finally, GAMMA Investing LLC lifted its position in shares of Axon Enterprise by 58,725.5% during the 1st quarter. GAMMA Investing LLC now owns 764,731 shares of the biotechnology company's stock valued at $402,210,000 after acquiring an additional 763,431 shares during the period. Institutional investors and hedge funds own 79.08% of the company's stock.

Insider Activity at Axon Enterprise

In related news, CFO Brittany Bagley sold 3,400 shares of the firm's stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $700.00, for a total value of $2,380,000.00. Following the transaction, the chief financial officer directly owned 131,833 shares in the company, valued at approximately $92,283,100. This trade represents a 2.51% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Michael Garnreiter sold 5,913 shares of the firm's stock in a transaction on Wednesday, June 4th. The stock was sold at an average price of $760.00, for a total transaction of $4,493,880.00. Following the completion of the sale, the director owned 17,740 shares in the company, valued at $13,482,400. This represents a 25.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 44,642 shares of company stock worth $30,500,428 over the last quarter. 4.40% of the stock is currently owned by corporate insiders.

Axon Enterprise Trading Down 9.0%

Shares of NASDAQ:AXON traded down $72.87 during mid-day trading on Thursday, hitting $732.99. The stock had a trading volume of 1,222,524 shares, compared to its average volume of 706,657. The company has a market cap of $57.06 billion, a PE ratio of 177.05, a P/E/G ratio of 90.96 and a beta of 1.29. The company's 50 day moving average is $748.40 and its 200-day moving average is $639.52. The company has a debt-to-equity ratio of 0.68, a quick ratio of 2.62 and a current ratio of 2.83. Axon Enterprise, Inc has a 12-month low of $279.02 and a 12-month high of $830.21.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share for the quarter, topping analysts' consensus estimates of $1.34 by $0.07. The business had revenue of $603.63 million for the quarter, compared to the consensus estimate of $585.67 million. Axon Enterprise had a net margin of 14.86% and a return on equity of 5.81%. Axon Enterprise's revenue for the quarter was up 31.3% compared to the same quarter last year. During the same period in the prior year, the business posted $1.15 earnings per share. On average, sell-side analysts predict that Axon Enterprise, Inc will post 5.8 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on AXON. Barclays raised their price objective on shares of Axon Enterprise from $726.00 to $735.00 and gave the stock an "overweight" rating in a research note on Friday, May 9th. Wolfe Research began coverage on shares of Axon Enterprise in a research note on Monday. They set an "outperform" rating for the company. Bank of America raised their price objective on shares of Axon Enterprise from $750.00 to $895.00 and gave the stock a "buy" rating in a research note on Wednesday, June 4th. Needham & Company LLC raised their price objective on shares of Axon Enterprise from $600.00 to $750.00 and gave the stock a "buy" rating in a research note on Thursday, May 8th. Finally, The Goldman Sachs Group raised their price objective on shares of Axon Enterprise from $730.00 to $830.00 and gave the stock a "buy" rating in a research note on Wednesday, May 14th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat.com, Axon Enterprise currently has a consensus rating of "Moderate Buy" and a consensus target price of $699.55.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.